Biotechnology & Life Sciences Group, Boult Wade Tennant, Verulam Gardens, London WC1X 8BT, UK Tel: +44 (0) 20 7430 7500 Fax: +44 (0) 20 7430 7600 E-mail: cbaldock@boult.com

Received 25 November 2005.

Abstract

The patenting of embryonic stem cell-related inventions appears to be as controversial as the technology itself. The author outlines the state of play in Europe and the USA as well as other selected territories. While Europe has the broadest statutory exclusions to patenting of inventions which might be regarded as unethical, it appears that a smooth ride for applicants and patent holders is not guaranteed elsewhere.